

Riya International Pte Ltd

October 25, 2021

Ratings

Facilities/Instruments	Amount (Rs. crore)	Ratings	Rating Action	
Short Term Bank Facilities 140.00		CARE A4; ISSUER NOT COOPERATING* (A Four ISSUER NOT COOPERATING*)	Rating continues to remain under ISSUER NOT COOPERATING category and Revised from CARE A4+; (A Four Plus)	
Total Facilities	140.00 (Rs. One Hundred Forty Crore Only)			

Details of instruments/facilities in Annexure-1

Detailed Rationale & Key Rating Drivers

CARE had, vide its press release dated November 13, 2020, placed the rating(s) of Riya International Pte Ltd (RIPL) under the 'issuer non-cooperating' category as RIPL had failed to provide information for monitoring of the rating and had not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. RIPL continues to be non-cooperative despite repeated requests for submission of information through e-mails, phone calls and a letter/email dated September 29, 2021, October 09, 2021, October 19, 2021.

In line with the extant SEBI guidelines, CARE has reviewed the rating on the basis of the best available information which however, in CARE's opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

The ratings assigned to the bank facilities of RIPL have been revised on account of non-availability of requisite information.

Detailed description of the key rating drivers

Please refer to PR dated November 13, 2020

Analytical approach: Standalone

Applicable Criteria

<u>Policy in respect of Non-cooperation by issuer</u> Policy on default recognition

About the Company

Riya International Pte. Ltd. (RIPL) is a wholly-owned step-down subsidiary of Gokul Agro Resources Limited (GARL). RIPL was originally incorporated in June 2015 as privately held company by Mr. Mehta Vijay Kumar and Mr. Kalyani Yogesh in Singapore. Later on, in April 2018 it was acquired by the Maurigo Pte. Ltd. (MPL) which is wholly owned subsidiary of GARL. RIPL is primarily an import arm of GARL to source crude edible oil (primarily CPO) from Malaysia & Indonesia for GARL's refining unit at Gandhidham, Gujarat. GARL is a publicly held company, managed by Mr. Kannubhai Thakkar and his family. GARL is in the business of seed crushing, extracting, refining and marketing of edible and non-edible oils. It has seed crushing capacity of 5,10,000 Metric tonnes per annum (MTPA), solvent extraction capacity of 7,20,000 MTPA, refinery capacity of 6,60,000 MTPA along with some other value-added processes such as fractionation, hydrogenation and other derivative production at its plant located at Gandhidham, Gujarat.

Brief Financials (Rs. crore)	FY19(A)*	FY20(A)*
Total operating income	834.26	1323.53
PBILDT	2.93	8.84
PAT	1.63	3.76
Overall gearing (times)	0.00	3.37
Interest coverage (times)	2.70	2.10

A: Audited

1 CARE Ratings Limited

Press Release



*P&L items are converted at yearly average exchange rate of 69.89 & 70.90 INR/USD for FY19 & FY20 respectively whereas B&S items are converted at year end closing exchange rate of 69.17 & 75.66 INR/USD as on March 31, 2019 & March 31, 2020 respectively.

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Disclosure of Interest of Independent/Non-Executive Directors and Managing Director & CEO of CARE: Not applicable

Rating History for last three years: Please refer Annexure-2

Covenants of rated instrument/facility: Annexure-3

Complexity level of various instruments rated for this company: Annexure-4

Annexure-1: Details of Instruments/Facilities

Name of the	ISIN	Date of	Coupon	Maturity	Size of the Issue	Rating assigned along with
Instrument		Issuance	Rate	Date	(Rs. crore)	Rating Outlook
Fund-based/Non-fund- based-Short Term		-	-	-	140.00	CARE A4; ISSUER NOT COOPERATING*

^{*}Issuer did not cooperate; Based on best available information

Annexure-2: Rating History of last three years

		Current Ratings			Rating history			
Sr. No.	Name of the Instrument/ Bank Facilities	Туре	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021-2022	Date(s) & Rating(s) assigned in 2020- 2021	Date(s) & Rating(s) assigned in 2019- 2020	Date(s) & Rating(s) assigned in 2018- 2019
1	Fund- based/Non- fund-based- Short Term	ST	140.00	CARE A4; ISSUER NOT COOPERATING*	-	1)CARE A4+; ISSUER NOT COOPERATING* (13-Nov-20)	1)CARE A4+ (30- Aug-19)	-

^{*}Issuer did not cooperate; Based on best available information

Annexure 3: Detailed explanation of covenants of rated instrument/facility: Not Applicable

Annexure 4: Complexity level of various instruments rated for this company:

Sr. No	Name of instrument	Complexity level		
1	Fund-based/Non-fund-based-Short Term	Simple		

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

2 CARE Ratings Limited



Contact us

Media Contact

Name: Mr. Mradul Mishra Contact no.: +91-22-6837 4424

Email ID: mradul.mishra@careratings.com

Analyst Contact

Name: Mrs. Shachee Vyas Contact no.: 079-40265665

Email ID: shachee.tripathi@careratings.com

Relationship Contact

Name: Mr. Deepak Prajapati Contact no.: 079-40265656

Email ID: deepak.prajapati@careratings.com

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

3 CARE Ratings Limited

^{**}For detailed Rationale Report and subscription information, please contact us at www.careratings.com